Renalytix PLC Shares Leap 45% After Diagnostic Test Partnership with Tempus AI

Strategic Insights -

Renalytix PLC, a diagnostics group, has seen its shares rise by 45% in early London trading following an agreement with US health technology company Tempus AI to expand access to its flagship kidneyintelX.dkd test. The partnership will make the blood test available across Tempus's network of American healthcare providers, benefiting the 15 million people in the US living with both type 2 diabetes and chronic kidney disease. The test, approved by the US FDA and reimbursed by Medicare, assesses the likelihood of disease progression and helps doctors tailor care accordingly. This deal will be the first in Tempus's chronic kidney disease portfolio, with samples processed at a Renalytix lab and results delivered digitally to clinicians and patients.

Key Takeaways:

  • Renalytix PLC shares have risen by 45% in early London trading following a partnership with US health technology company Tempus AI.
  • The agreement will make Renalytix's kidneyintelX.dkd test available across Tempus's network of American healthcare providers, covering 15 million people with type 2 diabetes and chronic kidney disease.
  • The test is approved by the US FDA and reimbursed by Medicare, helping doctors tailor care for patients.
  • The partnership will process samples at a Renalytix lab and deliver results digitally to clinicians and patients.
  • Integration into existing health system workflows will aid clinicians in taking earlier action to slow disease progression.
  • James McCullough, Renalytix CEO, stated the tie-up will expand patient and clinician access and accelerate innovation in the cardiovascular and metabolic space.
  • Ryan Fukushima, Tempus's COO, emphasized the partnership's potential to extend Tempus's reach into diabetes and kidney disease using AI-driven insights.

Statistics:

  • Renalytix PLC shares have risen by 45% in market value following the partnership with Tempus AI.
  • The agreement will increase access to the kidneyintelX.dkd test among the 15 million people in the US with both type 2 diabetes and chronic kidney disease.
  • The test is approved by the US FDA, making it a FDA-approved product.
  • Medicare reimburses the test, indicating its acceptance as a medically necessary procedure.
  • The partnership will cover over 15 million people in the US with type 2 diabetes and chronic kidney disease.

Sources:

  • Renalytix PLC ( AIM: RENX)
  • Tempus AI (US health technology company)
  • US FDA (approval of kidneyintelX.dkd test)
  • Medicare (reimbursement for kidneyintelX.dkd test)
  • James McCullough (Renalytix CEO)
  • Ryan Fukushima (Tempus COO)